SHAREHOLDER ALERT: FGEN RMO ACAD: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
NEW YORK, NY / ACCESSWIRE / June 4, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
FibroGen, Inc. (NASDAQ:FGEN)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/fibrogen-inc-loss-submission-form?prid=16585&wire=1
Lead Plaintiff Deadline: June 11, 2021
Class Period: October 18, 2017 - April 6, 2021
Allegations against FGEN include that: (i) the Company's prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia certain safety analyses submitted in connection with CKD included post-hoc changes to the stratification factors; (ii) FibroGen's analyses with the pre-specified stratification factors result in higher hazard ratios (point estimates of relative risk) and 95% confidence intervals; (iii) based on these analyses the Company could not conclude that roxadustat reduces the risk of (or is superior to) MACE+ in dialysis, and MACE and MACE+ in incident dialysis compared to epoetin-alfa; (iv) as a result, the Company faced significant uncertainty that its NDA for roxadustat as a treatment for anemia of CKD would be approved by the FDA; and (v) as a result of the foregoing, Defendants' statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Romeo Power, Inc. (NYSE:RMO)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/romeo-power-inc-loss-submission-form?prid=16585&wire=1
Lead Plaintiff Deadline: June 15, 2021
Class Period: October 5, 2020 - March 30, 2021
Allegations against RMO include that: (i) Romeo had only two battery cell suppliers, not four, (ii) the future potential risks that Defendants warned of concerning supply disruption or shortage had already occurred and were already negatively affecting Romeo's business, operations and business prospects, (iii) Romeo did not have the battery cell inventory to accommodate end-user demand and ramp up production in 2021, (iv) Romeo's supply constraint was a material hindrance to Romeo's revenue growth, and (v) Romeo's supply chain for battery cells was not hedged, but in fact, was totally at risk and beholden to just two battery cell suppliers and the spot market for their 2021 inventory. Given the supply constraint that Romeo was experiencing during the Class Period, Defendants had no reasonable basis to represent that the Company had the ability to meet customer demand and that it would support growth in revenue in 2021.
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/acadia-pharmaceuticals-inc-loss-submission-form?prid=16585&wire=1
Lead Plaintiff Deadline: June 18, 2021
Class Period: June 15, 2020 - April 4, 2021
Allegations against ACAD include that: (i) the materials submitted in support of the pimavanserin supplemental new drug application (sDNA) contained statistical and design deficiencies; (ii) accordingly, the pimavanserin sNDA lacked the evidentiary support that the Company had led investors to believe it possessed; (iii) the Food and Drug Administration Agency was unlikely to approve the pimavanserin sNDA in its present form; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
To learn more contact Vincent Wong, Esq. either via email email@example.com or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
Vincent Wong, Esq.
39 East Broadway
New York, NY 10002
SOURCE:The Law Offices of Vincent Wong
View source version on accesswire.com:
© 2021 Accesswire. All Rights Reserved.